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ORIGINAL RESEARCH
Differences in NT- proBNP Response and 
Prognosis in Men and Women With Heart 
Failure With Reduced Ejection Fraction
Melissa A. Daubert , MD; Eric Yow, MS; Huiman X. Barnhart, PhD; Ileana L. Piña , MD, MPH; Tariq Ahmad, MD; 
Eric Leifer, PhD; Lawton Cooper , MD, MPH; Patrice Desvigne- Nickens , MD; Mona Fiuzat, PharmD; 
Kirkwood Adams, MD; Justin Ezekowitz , MBBCh, MSc; David J. Whellan, MD, MHS; James L. Januzzi , MD; 
Christopher M. O’Connor, MD; G. Michael Felker , MD, MHS
BACKGROUND: NT- proBNP (N- terminal pro- B- type natriuretic peptide) is a prognostic biomarker in heart failure (HF) with re-
duced ejection fraction. However, it is unclear whether there is a sex difference in NT- proBNP response and whether the 
therapeutic goal of NT- proBNP ≤1000 pg/mL has equivalent prognostic value in men and women with HF with reduced ejec-
tion fraction.
METHODS AND RESULTS: In a secondary analysis of the GUIDE- IT (Guiding Evidence Based Therapy Using Biomarker Intensified 
Treatment) trial we analyzed trends in NT- proBNP and goal attainment by sex. Differences in clinical characteristics, HF treat-
ment, and time to all- cause death or HF hospitalization were compared. Landmark analysis at 3 months determined the prog-
nostic value of early NT- proBNP goal achievement in men and women. Of the 286 (32%) women and 608 (68%) men in the 
GUIDE- IT trial, women were more likely to have a nonischemic cause and shorter duration of HF. Guideline- directed medical 
therapy was less intense over time in women. The absolute NT- proBNP values were consistently lower in women; however, 
the change in NT- proBNP and clinical outcomes were similar. After adjustment, women achieving the NT- proBNP goal had an 
82% reduction in death or HF hospitalization compared with a 59% reduction in men.
CONCLUSIONS: Men and women with HF with reduced ejection fraction had a similar NT- proBNP response despite less in-
tensive HF treatment among women. However, compared with men, the early NT- proBNP goal of ≤1000 pg/mL had greater 
prognostic value in women. Future efforts should be aimed at intensifying guideline- directed medical therapy in women, which 
may result in greater NT- proBNP reductions and improved outcomes in women with HF with reduced ejection fraction.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT01685840.
Key Words: N- terminal pro- B- type natriuretic peptide ■ heart failure ■ women
The prevalence of heart failure (HF) with reduced ejection fraction (HFrEF) increases with age for both men and women; however, there are intrigu-
ing sex- specific differences in predisposing factors, 
medical treatment, health- related quality of life (QoL), 
and clinical outcomes.1– 3 Women with HFrEF are fre-
quently older and are more likely than men to have a 
nonischemic HF cause.3– 9 Women experience more 
severe symptoms and have a worse QoL for a similar 
burden of HF.3,10 Guideline- directed medical therapy 
(GDMT) is often underutilized in women, and women 
are less likely to be referred for cardiac rehabilitation 
and cardiac resynchronization therapy, despite the 
greater mortality benefits of these interventions in 
women compared with men.1– 3,5,11,12 Finally, there are 
conflicting data regarding clinical outcomes in women 
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with HFrEF. Some studies indicate higher rates of death 
and HF hospitalization, while others have found that 
women with HFrEF have fewer HF hospitalizations and 
lower mortality compared with men with HFrEF.3,4,13,14 
Further evaluation of the biological mechanisms un-
derlying these sex differences is needed to optimize 
the care of women with HFrEF.
Insight into the pathophysiologic underpinnings of 
sex- specific differences may be gained through ob-
servation of the longitudinal response in NT- proBNP 
(N- terminal pro- B- type natriuretic peptide), one of the 
more powerful diagnostic and prognostic biomarkers 
in HFrEF. Previous studies have evaluated baseline 
NT- proBNP concentrations and the association with 
clinical outcomes in men and women.15– 17 However, 
to date, no study has serially evaluated NT- proBNP 
and assessed the sex- specific NT- proBNP response 
and clinical outcomes in men and women with HFrEF. 
Furthermore, the therapeutic target of reducing NT- 
proBNP to <1000 pg/mL has been uniformly applied 
to both sexes; however, it is unclear whether this NT- 
proBNP goal has equivalent prognostic value in both 
men and women.
The GUIDE- IT (Guiding Evidence Based Therapy 
Using Biomarker Intensified Treatment) trial was a large, 
randomized clinical trial that evaluated the impact of 
biomarker- guided care at 45 sites in the United States 
and Canada by comparing NT- proBNP– guided man-
agement with usual care in the HFrEF population.18 In 
this secondary analysis of the GUIDE- IT trial, we stud-
ied the longitudinal trends in NT- proBNP among men 
and women with HFrEF in order to increase the under-
standing of sex- specific differences in HFrEF and iden-




Qualified researchers trained in human subject con-
fidentiality protocols may request access to the data 
that support the findings of this study by contact-
ing the National Heart, Lung, and Blood Institute 
Biological Specimen and Data Repository Information 
Coordination Center.
Study Design and Population
The study design and outcomes for the GUIDE- IT 
trial have been previously published.18,19 Briefly, be-
tween January 16, 2013, and September 20, 2016, 
stable patients with HFrEF (ejection fraction ≤40%) 
were enrolled and randomized to a strategy of usual 
care with NT- proBNP guidance or usual clinically di-
rected care. Patients in the biomarker- guided arm 
were treated with usual care plus serial NT- proBNP 
measurements with a goal to decrease NT- proBNP 
concentration <1000  pg/mL, whereas those in the 
usual care arm received standard clinically guided 
care. Patients were to be followed for a minimum 
of 12  months and a maximum of 24  months. The 
GUIDE- IT trial was designed to include 1100 patients 
but was stopped by the data safety monitoring board 
for futility after 894 patients (81% of planned) were 
enrolled.18 No difference in achieved NT- proBNP 
concentrations or clinical outcomes was found be-
tween the study arms and the medical management 
of both study groups was comparable. The study 
CLINICAL PERSPECTIVE
What Is New?
• In a population with advanced heart failure with 
reduced ejection fraction, women were treated 
less intensely with guideline- directed medical 
therapy than men.
• Absolute NT- proBNP (N- terminal pro- B- type 
natriuretic peptide) values were consistently 
lower in women, yet the adjusted change in NT- 
proBNP, NT- proBNP early goal achievement, 
and clinical outcomes were similar between 
men and women with heart failure with reduced 
ejection fraction.
What Are the Clinical Implications?
• Among men and women achieving the NT- 
proBNP goal of ≤1000  pg/mL at 3  months, 
there was a lower rate of death and heart failure 
hospitalization in women than in men, suggest-
ing that women with heart failure with reduced 
ejection fraction may derive greater benefit from 
early NT- proBNP reductions.
Nonstandard Abbreviations and Acronyms
CHAMP- HF Change the Management of 
Patients With Heart Failure
GDMT guideline- directed medical therapy
GUIDE- IT Guiding Evidence Based Therapy 
Using Biomarker Intensified 
Treatment
HFrEF heart failure with reduced 
ejection fraction
KCCQ Kansas City Cardiomyopathy 
Questionnaire
KorHF Korean Heart Failure Registry
NT- proBNP N- terminal pro- B- type natriuretic 
peptide
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was funded by the National Heart, Lung, and Blood 
Institute and approved by the institutional review 
board at each study site. All patients provided writ-
ten informed consent to participate.
In both study arms, NT- proBNP levels were 
collected at baseline and every 3  months through 
12 months and analyzed at a central core laboratory. 
Patients and providers were blinded to core labo-
ratory NT- proBNP results. In the biomarker- guided 
arm, NT- proBNP levels were also ascertained at 
local laboratories for use by treating providers. 
The study protocol specified clinical interventions 
to be considered to achieve the NT- proBNP goal 
of <1000  pg/mL, but specific management deci-
sions were at the discretion of the treating physi-
cian. Patients randomized to the usual care group 
received treatment based on clinical practice guide-
lines. Sites were asked not to perform open- label 
assessment of natriuretic peptides in the usual care 
group. Provider reasons for not titrating HF medica-
tions were collected at study visits.
All patients with an NT- proBNP measurement at 
baseline were included in this analysis cohort. Clinical 
characteristics, serial NT- proBNP concentrations, 
GDMT, and clinical outcomes through 24  months 
were evaluated according to sex. The GDMT score, 
as reported by Januzzi et al,20 was used to assess 
sex differences in treatment with HF therapies asso-
ciated with mortality reduction in HFrEF. The primary 
clinical outcome was time to a composite of all- cause 
death or HF hospitalization. Secondary outcomes 
were time to all- cause death, time to HF hospital-
ization, time to cardiovascular hospitalization, and 
time to a composite of cardiovascular death or HF 
hospitalization. All adverse events were adjudicated 
by a clinical end point committee using prespecified 
criteria. Health- related QoL was measured using the 
Kansas City Cardiomyopathy Questionnaire (KCCQ), 
which is scored 0 to 100, with lower scores indicating 
a poorer health status.
Statistical Analysis
Descriptive data are presented as frequencies and 
percentages for categorical variables and mean±SD 
or median with 25th and 75th interquartile range 
(IQR) for continuous variables. For continuous vari-
ables, differences were assessed using Wilcoxon 
rank sum test, and for categorical variables, differ-
ences were assessed using chi- square test. In the 
case of low cell counts, the treatment group differ-
ences were tested using Fisher exact method. For 
count data, such as medication adjustments and 
visit frequency, Poisson regression with offset of 
follow- up time was used to assess differences. Sex 
differences in NT- proBNP concentrations were ad-
justed for age, race, body mass index (BMI), chronic 
kidney disease, diabetes mellitus, and ischemic car-
diomyopathy.21 For time- to- event analyses, with time 
starting at randomization, unadjusted event rates 
were estimated using Kaplan- Meier curves and 95% 
CIs; group differences were tested using log- rank 
test. Cox proportional hazards regression models 
were used to examine the associations between sex 
and outcomes while adjusting for covariates that 
were statistically significant in the univariate model 
or clinically relevant. The covariates included were 
age, race, BMI, hypertension, diabetes mellitus, 
smoking, chronic kidney disease, peripheral artery 
disease, atrial fibrillation, coronary artery disease, 
ischemic cardiomyopathy, myocardial infarction, 
New York Heart Association class III/IV, ejection 
fraction, duration of HF, log of baseline NT- proBNP, 
biomarker- guided arm, and QoL by KCCQ score. 
To minimize bias attributable to missing variables, 
multiple imputation using the fully conditional speci-
fication method was implemented for the modeling. 
Landmark time- to- event analyses at 3 months were 
performed on patients alive at that time. Cox regres-
sion analysis was performed and included the same 
covariates as above, as well as median visit count 
until the landmark, median dose adjustment until the 
landmark, GDMT score at the landmark, log of 3- 
month NT- proBNP, and NT- proBNP ≤1000 pg/mL at 
the landmark. To assess whether there was a dif-
ferential benefit for women and men who achieved 
the NT- proBNP goal at 3 months, we assessed the 
interaction of sex and NT- proBNP goal achievement 
at the landmark in the Cox regression analysis. An 
exploratory analysis of adjusted data used a grid 
search to find the 3- month NT- proBNP concentra-
tion in men and women at which there was a shift in 
linear association with the time- to- event outcome of 
death or HF hospitalization.22 A 2- piece cubic spline 
model with transformation was used to demonstrate 
the optimal 3- month NT- proBNP cut point, defined 
as the NT- proBNP concentration below which there 
was a significant decrease in the adjusted hazard for 
death or HF hospitalization. The threshold for statis-
tical significance was 2- sided with a type I error rate 
of 0.05. The assumption of proportional hazards for 
sex was assessed using supremum test and found 
to be nonsignificant in the Cox regression models. 
Analyses were performed using SAS version 9.4 
(SAS Institute Inc.).
RESULTS
There were 286 (32%) women and 608 (68%) men in 
the GUIDE- IT trial (Figure 1). The baseline characteristics 
of men and women are shown in Table 1. Women had 
greater racial diversity, a higher BMI, and fewer coronary 
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were more likely to have a nonischemic HF cause, a 
shorter duration of HF, and a higher ejection fraction at 
baseline, but, compared with men, women had a lower 
QoL score. There was no difference in biomarker- guided 
therapy allocation according to sex. Pharmacologic 
treatment by medication class was similar between men 
and women at baseline (Table 2). A relatively low per-
centage of either sex were at ≥100% of the target dose 
for β- blockers and angiotensin- converting enzyme in-
hibitors (ACEIs) or angiotensin II receptor blockers (ARBs) 
at baseline. However, the GDMT score was significantly 
lower in women at baseline, 3 months, and 12 months. 
At 1 year, a significantly greater percentage of men than 
women were titrated up to ≥100% of target doses of β- 
blockers and a similar trend was seen for ACEIs or ARBs 
(Figure 2). Women had significantly fewer dose adjust-
ments than men: 4.0 (IQR, 2.0– 7.0) versus 5.0 (IQR, 2.0– 
8.0) (P<0.001). Reasons for not titrating dose are listed in 
Figure 3 and differed between men and women. Women 
also had significantly fewer clinical visits compared with 
men: 9.3±5.0 versus 10.0±5.8, respectively (P=0.002).
The absolute NT- proBNP values were consistently 
lower in women; however, the trend in NT- proBNP 
among men and women with HFrEF was similar 
over time (Figure  4). Univariate analysis of the sex- 
specific NT- proBNP response revealed that women 
had a significantly lower NT- proBNP concentration 
by 3  months, but after adjusting for age, race, BMI, 
chronic kidney disease, diabetes mellitus, and 
ischemic cardiomyopathy, there were no significant 
sex differences in NT- proBNP response (Table 3). The 
median follow- up for clinical events was 14.7 months 
(IQR, 6.6– 23.5 months) with a similar duration in men 
and women (14.7 months [IQR, 6.7– 23.7 months] and 
14.9 months [IQR, 6.2– 22.6 months], respectively). 
There was no difference between men and women 
for the primary outcome of all- cause death or HF 
hospitalization (Figure  5). Unadjusted analysis of 
secondary outcomes demonstrated significantly fewer 
deaths among women at 12  months; however, this 
did not remain statistically significant after adjustment 
(Table 4).
To further explore the impact of early NT- proBNP 
goal achievement on outcomes among men and 
women, a 3- month landmark analysis was performed 
and included the 697 (77.9%) patients who were alive 
and had a 3- month NT- proBNP concentration. The 
analysis excluded 197 patients, of whom 49 had died, 
53 had <3 months of follow- up, and 95 were missing 
Figure 1. CONSORT diagram.
Study flow diagram of secondary analysis population and 
subgroup. GUIDE- IT indicates Guiding Evidence Based Therapy 
Using Biomarker Intensified Treatment; and NT- proBNP, N- 














Table 1. Baseline Clinical Characteristics in Men and 
Women in GUIDE- IT
Women (n=286) Men (n=608) P Value
Age, y 60.6±15.0 61.9±13.3 0.36
Race (Black) 127 (44.4) 197 (32.4) <0.001
BMI, kg/m2 31.8±9.6 29.5±7.2 0.001
Hypertension 210 (73.4) 496 (81.6) 0.008
Hyperlipidemia 157 (54.9) 367 (60.4) 0.15
Diabetes mellitus 142 (49.7) 268 (44.1) 0.13
Smoking 80 (28.0) 224 (36.8) 0.01
Atrial fibrillation 99 (34.6) 259 (42.6) 0.03
Chronic kidney 
disease
87 (32.4) 243 (40.0) 0.007
Peripheral artery 
disease
17 (5.9) 77 (12.7) 0.002
Coronary artery 
disease
102 (35.7) 308 (50.7) <0.001
Myocardial 
infarction
54 (18.9) 197 (32.4) <0.001
Ischemic 
cardiomyopathy
111 (38.8) 336 (55.3) <0.001
HF duration*, mo 8 (1.0– 48.0) 20 (1.0– 72.0) 0.003









139 (48.6) 307 (50.5) 0.62
Values are mean±SD or number (percentage) unless otherwise noted. 
BMI indicates body mass index; GUIDE- IT, Guiding Evidence Based Therapy 
Using Biomarker Intensified Treatment; HF, heart failure; KCCQ, Kansas City 
Cardiomyopathy Questionnaire; NYHA, New York Heart Association; and 
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the 3- month NT- proBNP measurement. Differences 
in clinical characteristics between men and women 
in this subgroup were similar to that of the whole co-
hort (Table  S1). In the 3- month landmark analysis of 
the primary outcome of death or HF hospitalization, 
there was no difference between men and women for 
the primary outcome after adjustment (hazard ratio 
[HR], 1.11; 95% CI, 0.82– 1.51 [P=0.48]). However, lon-
ger HF duration increased the hazard for death or HF 
hospitalization (HR, 1.22; 95% CI, 1.12– 1.34 [P<0.001]), 
while achieving the NT- proBNP goal of ≤1000 pg/mL 
at 3 months decreased the hazard (HR, 0.41; 95% CI, 
0.25– 0.68 [P<0.001]).
Evaluation of sex differences in NT- proBNP goal 
achievement at 3 months revealed that women were 
more likely to achieve the early goal, but this did not 
remain statistically significant after adjustment for 
clinical characteristics and HF treatment (odds ratio 
[OR], 0.50; 95% CI, 0.08– 3.03 [P=0.45]). However, 
among women achieving the NT- proBNP ≤1000 pg/
mL at 3 months, there was an 82% reduction in death 
or HF hospitalization (HR, 0.18; 95% CI, 0.07– 0.45 
[P<0.001]). In comparison, men achieving the early 
NT- proBNP goal had a 59% reduction in the primary 
outcome (HR, 0.41; 95% CI, 0.25– 0.68 [P<0.001]) 
(Figure 6). Exploration of the interaction between sex 
and achieved 3- month NT- proBNP goal on clinical 
outcomes suggested a trend that women benefitted 
more than men from early NT- proBNP goal achieve-
ment (interaction P=0.11).
Additionally, the 3- month NT- proBNP concentra-
tion below which women had a significant reduction 
in the adjusted hazard for the primary outcome was 
substantially lower than the NT- proBNP threshold in 
men (Figure  S1). After adjustment, an NT- proBNP 
threshold of ≤5410  pg/mL at 3  months was as-
sociated with a significantly lower rate of death or 
HF hospitalization in men, whereas an NT- proBNP 
threshold of ≤1260 pg/mL at 3 months was predic-
tive of lower mortality or HF hospitalization in women. 
Furthermore, the magnitude of benefit of lowering NT- 
proBNP was greater for women. For every 100- pg/
mL reduction in NT- proBNP below the sex- specific 
threshold, women had a 21% lower rate of death 
or HF hospitalization (HR, 0.79; 95% CI, 0.68– 0.91 
[P=0.001]), whereas men only had a 4% reduction in 
the primary outcome (HR, 0.96; 95% CI, 0.95– 0.98 
[P<0.001]).
DISCUSSION
This secondary analysis of the GUIDE- IT trial revealed 
important insights about sex- specific management and 
the longitudinal NT- proBNP response among men and 
women with HFrEF. Compared with men, women had 
fewer clinical risk factors and received less intensive 
GDMT, especially by 12 months. Exploratory analysis 
suggested that when the difference in clinical risk and 
intensity of HF treatment between men and women is 
adjusted for, early NT- proBNP goal achievement may 
benefit women more than men. Furthermore, incre-
mental reductions in NT- proBNP below sex- specific 
thresholds have greater prognostic significance in 
women than men.
Similar to prior studies, women with HFrEF in the 
GUIDE- IT trial were more racially diverse, had higher 
BMIs and fewer coronary artery disease risk factors, 
and were more likely to have a nonischemic cause of 
HF.3– 5,7,9 Baseline KCCQ scores were significantly lower 
Table 2. Pharmacologic Treatment in Men and Women in 
the GUIDE- IT Trial
Women (n=286) Men (n=608) P Value
Medications at baseline (% of patients)
ACEI or ARB 78.1 80.1 0.53




GDMT score* 6 (4– 8) 7 (4– 9) <0.001
Percentage at ≥100% of target dose at baseline
ACEI or ARB 15.0 20.3 0.11




Medications at 3 mo (% of patients)
ACEI or ARB 79.5 77.1 0.51




GDMT score* 7 (5– 10) 8 (5.75– 10) 0.017
Percentage at ≥100% of target dose at 3 mo
ACEI or ARB 21.5 26.3 0.25




Medications at 1 y (% of patients)
ACEI or ARB 73.8 78.1 0.31




GDMT score* 7 (4.5– 10) 8 (6– 11) 0.009
Percentage at ≥100% of target dose at 1 y
ACEI or ARB 22. 31.8 0.08




ACEI indicates angiotensin- converting enzyme inhibitor; ARB, angiotensin 
II receptor blocker; GDMT, guideline directed medical therapy; and GUIDE- IT, 
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among women than men, despite having a shorter du-
ration of HF and a higher mean ejection fraction. This 
sex disparity in KCCQ scores has also been observed 
in other HFrEF studies and warrants further investiga-
tion as to why HF imparts a lower QoL among women 
than men.3,10 A greater understanding of psychosocial 
factors and the influence of comorbid conditions, such 
as anxiety and depression, that may be contributing 
to these sex differences could allow for more targeted 
therapeutic strategies.
Earlier HFrEF studies have reported pharmaco-
logic undertreatment of women at baseline; however, 
more contemporary studies demonstrate this treat-
ment differential is narrowing.3– 5,9,15 Yet even in these 
more recent studies, treatment was largely defined 
as the percent utilization in each class of GDMT. In 
contrast, the GUIDE- IT trial uniquely captured phar-
macologic treatment over time with granular detail 
about the percentage of patients at or above target 
doses of GDMT and reasons for not titrating dose 
during clinical visits.23 In this sex- stratified treatment 
analysis, a similar proportion of men and women 
were taking guideline- recommended medications for 
HF at baseline; however, women were at significantly 
Figure 2. Sex differences in target dosing of guideline- directed medical therapy (GDMT) at 1 year.
Pie charts indicating the proportion of men and women achieving target doses of β- blocker therapy (top row) and angiotensin- 
converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) therapy (bottom row) at 1 year. Men were significantly more 
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lower GDMT intensity at baseline and throughout the 
course of the study, indicating a lower dose application 
of HF therapies known to have a mortality benefit. At 
1 year, men were significantly more likely to be at or 
above the target dose for β- blockers compared with 
women, and a similar trend was noted for ACEIs or 
ARBs. These results are consistent with findings from 
the CHAMP- HF (Change the Management of Patients 
With Heart Failure) registry, which found that female 
sex was associated with lower utilization of β- blockers 
and ACEIs or ARBs.24 This undertreatment of women 
has important implications for clinical outcomes and is 
also significant for the potential impact on NT- proBNP. 
Januzzi et al20 demonstrated that escalating the dose 
of β- blocker therapy has the greatest influence on low-
ering NT- proBNP concentrations (OR, 1.38; 95% CI, 
1.10– 1.72 [P=0.005]) followed by ACEI therapy (OR, 
1.11; 95% CI, 1.01– 1.21 [P=0.03]). Had women been 
treated as intensely as men over time with GDMT, 
women may have achieved even lower concentrations 
of NT- proBNP. Efforts should be made to increase the 
intensity of GDMT in order to optimize HF treatment 
and improve clinical outcomes in women with HFrEF.
The lower achievement of target dose and under-
treatment among women is at least partly explained 
by the fewer dose titrations in women compared with 
men. Provider reasoning for not titrating dose differed 
between men and women with men more often being 
"at the maximum tolerated dose," while women were 
not titrated because they were "below NT- proBNP 
goal" or because of the provider’s "clinical decision." 
Lack of titrating as a result of achieving the NT- proBNP 
goal may disadvantage women more than men. In the 
landmark analysis, women only began to have a signif-
icant reduction in adverse outcomes once NT- proBNP 
concentrations were <1260  pg/mL at 3  months. 
Therefore, women in whom GDMT was not intensified 
were denied the benefit that further biomarker reduc-
tion could have potentially conferred. Lack of dose 
titration because of the provider’s discretion may re-
flect that women with HFrEF are perceived differently 
than men with HFrEF and such sex bias can influence 
clinical HF management.25– 27 Greater understanding 
of these perceived differences is needed to overcome 
the obstacles that may hinder the intensifying GDMT 
in women.
This is the first study, to our knowledge, to lon-
gitudinally evaluate the sex- specific NT- proBNP 
response to HF treatment and assess the associa-
tion with clinical outcomes in men and women with 
HFrEF. Furthermore, existing data are conflicting as 
to whether NT- proBNP has the same prognostic sig-
nificance in men and women with HFrEF.15,16 In the 
study by Franke and colleagues,15 NT- proBNP was 
Figure 3. Reasons for not titrating medications by sex.





 http://ahajournals.org by on June 13, 2021
J Am Heart Assoc. 2021;10:e019712. DOI: 10.1161/JAHA.120.019712 8
Daubert et al Sex Differences in NT- proBNP in HFrEF
found to be equally predictive of mortality in men and 
women. In contrast, an analysis of KorHF (Korean 
Heart Failure Registry) found that NT- proBNP had 
greater predictive value for death and HF readmis-
sion in men than women.16
In GUIDE- IT, women had lower absolute NT- proBNP 
concentrations; however, the difference NT- proBNP 
goal achievement and absolute NT- proBNP reduction 
was not significantly different after adjustment for fac-
tors known to influence NT- proBNP levels.21 This could 
Figure 4. Change in NT- proBNP (N- terminal pro- B- type natriuretic peptide) in men and women with heart failure with 
reduced ejection fraction.









Male 608 480 392 331 308 230 187 151 131
Female 286 217 182 144 140 107 81 68 57
Table 3. NT- proBNP Response According to Sex
Women (n=286) Men (n=608) Unadjusted P Value Adjusted P Value*
NT- proBNP (pg/mL) at baseline 2349 (1382 to 4946) 2803 (1521 to 5573) 0.10 0.56
NT- proBNP (pg/mL) at 3 mo 1587 (623 to 3343) 2086 (883 to 4250) 0.01 0.61
NT- proBNP <1000 at 3 mo 79 (36.4) 135 (28.1) 0.03 0.46
NT- proBNP Δ from baseline to 3 mo −401 (−1416 to 281) −543 (−1709 to 280) 0.69 0.91
NT- proBNP (pg/mL) at 6 mo 1351 (446 to 3510) 1685 (748 to 4093) 0.09 0.99
NT- proBNP <1000 at 6 mo 77 (42.3) 129 (32.9) 0.03 0.17
NT- proBNP Δ from baseline to 6 mo −554 (−1650 to 517) −644 (−1861 to 358) 0.51 0.77
NT- proBNP (pg/mL) at 9 mo 1116 (361 to 2909) 1549 (600 to 3205) 0.07 0.67
NT- proBNP <1000 at 9 mo 61 (42.4) 105 (31.7) 0.03 0.09
NT- proBNP Δ from baseline to 9 mo −574 (−2005 to 73) −814 (−2244 to 151) 0.38 0.87
NT- proBNP (pg/mL) at 12 mo 1201 (387 to 2679) 1404 (529 to 3263) 0.15 0.15
NT- proBNP <1000 at 12 mo 65 (46.4) 126 (40.9) 0.30 0.63
NT- proBNP Δ from baseline to 12 mo −661 (−2003 to 214) −829 (−2256 to 127) 0.63 0.98
Values are median (interquartile range) or number (% of evaluable patients). Δ indicates change; and NT- proBNP, N- terminal pro- B- type natriuretic peptide.
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explain the similar clinical outcomes between men 
and women. Greater reductions in NT- proBNP have 
been associated with improved clinical outcomes.28 
It is possible that if women had received GDMT of 
equivalent intensity through 12 months, they may have 
had a greater absolute reduction in NT- proBNP and 
Figure 5. Clinical outcomes in men and women with heart failure (HF) with reduced ejection fraction.
The Kaplan- Meier curves for the primary outcome of death or HF hospitalization (upper left) and secondary outcomes of death 




p = 0.77 p = 0.66 
p = 0.86 p = 0.17 
Table 4. Clinical Outcomes in Men and Women With HFrEF Through 24 Months
Women* (n=286) Men* (n=608)
Unadjusted HR 
(95% CI) P Value
Adjusted HR† 
(95% CI) P Value
12 mo
Composite: death or HF 
hospitalization
85 (34.6) 198 (36.5) 0.94 (0.73 to 1.21) 0.64 0.91 (0.69 to 1.20) 0.49
Death 21 (8.9) 74 (14.4) 0.61 (0.37 to 0.99) 0.04 0.72 (0.43 to 1.21) 0.22
HF hospitalization 78 (32.0) 164 (31.0) 1.04 (0.80 to 1.36) 0.77 1.02 (0.76 to 1.37) 0.91
Cardiovascular hospitalization 134 (54.4) 309 (56.8) 0.91 (0.74 to 1.11) 0.36 0.87 (0.70 to 1.08) 0.20
Composite: cardiovascular 
death or HF hospitalization
84 (34.3) 190 (35.1) 0.97 (0.75 to 1.25) 0.81 0.92 (0.69 to 1.21) 0.55
24 mo
Composite: death or HF 
hospitalization
101 (35.3) 243 (40.0) 0.93 (0.74 to 1.17) 0.54 0.96 (0.75 to 1.24) 0.77
Death 38 (21.3) 105 (24.3) 0.78 (0.54 to 1.13) 0.19 0.91 (0.61 to 1.37) 0.66
HF hospitalization 89 (40.3) 199 (43.1) 1.0 (0.78 to 1.28) 0.98 1.03 (0.78 to 1.35) 0.86
Cardiovascular hospitalization 145 (62.5) 351 (70.1) 0.87 (0.72 to 1.06) 0.16 0.86 (0.70 to 1.07) 0.17
Composite: cardiovascular 
death or HF hospitalization
98 (44.0) 230 (47.7) 0.95 (0.75 to 1.20) 0.68 0.96 (0.74 to 1.24) 0.75
HF indicates heart failure; HFrEF, heart failure with reserved ejection fraction; and HR, hazard ratio.
*Event rates are expressed as number (percentage).
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fewer clinical events compared with men. This would 
be consistent with previous studies that have demon-
strated better clinical outcomes among women with 
HFrEF.3,13
Early achievement of the NT- proBNP goal of 
≤1000 pg/mL is associated with significantly better 
outcomes than those not attaining goal.20 After ad-
justment for clinical risk and HF treatment through 
3 months, there was no sex difference in the ability 
to achieve the early NT- proBNP goal of ≤1000  pg/
mL. However, women achieving the NT- proBNP goal 
of ≤1000 pg/mL at 3 months had a clinically signifi-
cant lower rate of death and HF hospitalization than 
men achieving the early NT- proBNP goal (82% ver-
sus 59%, respectively). This difference did not meet 
statistical significance, likely because of the smaller 
number of patients in the landmark analysis and fewer 
events that consequently limited the power to detect 
a statistical difference. Nonetheless, these findings 
are still clinically meaningful and extend the current 
knowledge by suggesting that the early NT- proBNP 
goal of ≤1000  pg/mL may have greater prognostic 
significance in women than men. This finding is fur-
ther supported by the observation that the prespec-
ified therapeutic NT- proBNP goal of ≤1000  pg/mL 
was over 5 times lower than the adjusted NT- proBNP 
threshold of 5410  pg/mL needed for risk reduction 
in men; however, it was only minimally lower than 
the adjusted NT- proBNP threshold of 1260  pg/mL 
needed for women to demonstrate a reduction in ad-
verse events. In other words, since the sex- specific 
NT- proBNP threshold for risk reduction was lower 
in women, there was greater benefit with incremen-
tal NT- proBNP reductions than in men, whose sex- 
specific NT- proBNP threshold was higher. This likely 
explains why women derived greater clinical benefit 
from lower NT- proBNP concentrations at 3 months 
than men.
Limitations
Several caveats should be considered in the inter-
pretation of these results. First, women only com-
prised one third of the GUIDE- IT study population; 
therefore, it is possible that additional sex differ-
ences exist but were not detected because of the 
sample size and the abbreviated follow- up period 
with a relatively low number of events second-
ary to early trial termination. Efforts are needed to 
achieve equity in trial enrollment so that when sex 
differences exist, they can be detected and used 
Figure 6. Clinical outcomes in men and women by early NT- proBNP (N- terminal pro- B- type natriuretic peptide) goal 
achievement.
Clinical outcomes were similar between men and women not achieving the early NT- proBNP goal (blue and red dashed lines). However, 
separation of the solid curves suggests a trend towards fewer events among women achieving the early NT- proBNP goal compared 
with men achieving the early NT- proBNP goal.
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to inform sex- specific HF management. Second, 
although this study included an in- depth analysis 
of treatment differences between men and women 
with HFrEF, treatment with neprilysin inhibitors, a 
therapy that can lead to substantial NT- proBNP re-
duction, was not common in clinical practice dur-
ing the timeframe in which the GUIDE IT trial was 
conducted. However, neprilysin inhibition does not 
appear to have a differential effect in men com-
pared with women.29,30 Finally, a landmark analysis 
at 12 months may have revealed whether the less 
intense GDMT in women negatively impacted NT- 
proBNP goal achievement and clinical outcomes 
more than men. Yet, such an analysis would have 
low power to detect a difference attributable to an 
even smaller population than in the 3- month land-
mark subgroup, which may not reflect the overall 
GUIDE- IT population as a result of survivor bias, 
and been limited by shorter follow- up duration 
with fewer events. Furthermore, the clinical value 
of a 12- month NT- proBNP analysis is uncertain. 
In contrast, the 3- month landmark is informative 
for guiding clinical management and informing the 
prognosis of men and women with HFrEF.
CONCLUSIONS
This study revealed several important insights on HF 
treatment, NT- proBNP response, and clinical out-
comes among men and women with HFrEF. Women 
were undertreated with regards to target dosing of β- 
blockers and ACEIs or ARBs. Future efforts should be 
aimed at intensifying GDMT, achieving target doses, 
and reducing NT- proBNP in women, which may have 
even greater benefit for women than men.
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Age (years) 59.9±15.1 62.0±12.8 0.18 
Race (Black) 97 (44.7%) 148 (30.8%) <0.001 
Body mass index (kg/m2) 32.5±10.1 29.4±7.1 <0.001 
Hypertension 155 (71.4%) 391 (81.5%) 0.004 
Hyperlipidemia 120 (55.3%) 288 (60.0%) 0.25 
Diabetes mellitus 109 (50.2%) 213 (44.4%) 0.16 
Smoking 52 (24.0%) 174 (36.3%) 0.001 
Atrial fibrillation 72 (33.2%) 206 (42.9%) 0.02 
Chronic kidney disease 63 (29.0%) 186 (38.8%) 0.01 
Peripheral artery disease 8 (3.7%) 61 (12.7%) <0.001 
Coronary artery disease 68 (31.3%) 245 (51.0%) <0.001 
Myocardial infarction 38 (17.5%) 155 (32.3%) <0.001 
Ischemic cardiomyopathy 75 (34.6%) 267 (55.6%) <0.001 
Heart Failure Duration* (mos) 6 (1.0-45.0) 20 (1.0-72.0) 0.003 
NYHA Class III/IV 88 (40.6%) 195 (41.1%) 0.93 
Ejection Fraction (%) 25.0±8.3 23.9±8.4 0.09 
Biomarker-guided Therapy 106 (48.8%) 243 (50.6%) 0.68 
Quality of Life Score by KCCQ 54.5±21.0 59.9±22.1 0.002 
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Figure S1. Relationship between 3-month NT-proBNP and Death or HF Hospitalization. 
 



















The vertical red line indicates the inflection point at which there was a significant decrease in the 
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